HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Longtime Shareholders in Regeneron Pharmaceuticals (REGN) to Contact its Attorneys: Firm Investigating Possible Breach of Fiduciary Duties

Regeneron Pharmaceuticals (REGN) Shareholder Investigation:

The investigation focuses on whether Regeneron's directors breached their oversight duties by disregarding senior management's alleged violation of Medicare's anti-kickback laws.

Regeneron's Eylea drug treats macular degeneration, the leading cause of blindness in seniors.  The pricey drug, which costs over $10,000 per year, has become Regeneron's flagship product.  The federal government is among Eylea's greatest sources of revenue through Medicare.

"We're focused on whether Regeneron's Board failed to monitor senior management, and if Regeneron has suffered resulting damages," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of Regeneron and suffered losses, click here to discuss your legal rights with Hagens Berman.

Contact:
Reed Kathrein, 844-916-0895

SOURCE Hagens Berman Sobol Shapiro LLP

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.


Posted In: